These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12006210)

  • 1. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
    Prince HM; Wall D; Rischin D; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Wolf M; Januszewicz EH; Westerman D; Richardson G; Scarlett J; Briggs P
    Cytotherapy; 2002; 4(2):147-55. PubMed ID: 12006210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
    Prince HM; Bashford J; Wall D; Rischin D; Parker N; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Francis P; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Cytotherapy; 2002; 4(2):137-45. PubMed ID: 12006209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
    Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
    J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
    Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
    Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel effectively mobilizes peripheral blood CD34+ cells.
    Prince HM; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Wall D; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Rischin D
    Bone Marrow Transplant; 2000 Sep; 26(5):483-7. PubMed ID: 11019836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
    Blystad AK; Holte H; Kvaløy S; Smeland E; Delabie J; Kvalheim G
    Bone Marrow Transplant; 2001 Nov; 28(9):849-57. PubMed ID: 11781645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
    Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
    J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.
    Weaver CH; Hazelton B; Birch R; Palmer P; Allen C; Schwartzberg L; West W
    Blood; 1995 Nov; 86(10):3961-9. PubMed ID: 7579367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
    Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
    Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
    De Rosa L; Anghel G; Pandolfi A; Riccardi M; Amodeo R; Majolino I
    Int J Hematol; 2004 Jan; 79(1):85-91. PubMed ID: 14979484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients.
    Richel DJ; Johnsen HE; Canon J; Guillaume T; Schaafsma MR; Schenkeveld C; Hansen SW; McNiece I; Gringeri AJ; Briddell R; Ewen C; Davies R; Freeman J; Miltenyi S; Symann M
    Bone Marrow Transplant; 2000 Feb; 25(3):243-9. PubMed ID: 10673694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
    Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
    Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.